Protein metabolism in glucocorticoid excess: study in Cushing’s syndrome and the effect of treatment

Morton G. Burt,1,2,3 James Gibney,1 and Ken K. Y. Ho1,2,3

1Pituitary Research Unit, Garvan Institute of Medical Research; 2Department of Endocrinology, St. Vincent’s Hospital; and 3University of New South Wales, Sydney, New South Wales, Australia

Submitted 26 September 2006; accepted in final form 19 January 2007

Burt MG, Gibney J, Ho KK. Protein metabolism in glucocorticoid excess: study in Cushing’s syndrome and the effect of treatment. Am J Physiol Endocrinol Metab 292: E1426–E1432, 2007. First published January 23, 2007; doi:10.1152/ajpendo.00524.2006.—How protein metabolism is perturbed during chronic glucocorticoid excess is poorly understood. The aims were to investigate the impact of chronic glucocorticoid excess and restoration of eucortisol in Cushing’s syndrome (CS) on whole body protein metabolism. Eighteen subjects with CS and 18 normal subjects (NS) underwent assessment of body composition using DEXA and whole body protein turnover with a 3-h constant infusion of [1-13C]leucine, allowing calculation of rates of leucine appearance (leucine Ra), leucine oxidation (Lox), and leucine incorporation into protein (LIP). Ten subjects with CS were restudied after restoration of eucortisolemia. Percentage FM was greater (43.9 ± 1.6 vs. 33.8 ± 2.4%, P = 0.002) and LBM lower (52.7 ± 1.6 vs. 62.1 ± 2.3%, P = 0.002) in CS. LBM was significantly correlated (r2 > 0.44, P < 0.005) to leucine Ra, Lox, and LIP in both groups. After correcting for LBM, leucine Ra (133 ± 5 vs. 116 ± 5 μmol/min, P = 0.02) and Lox (29 ± 1 vs. 24 ± 1 μmol/min, P < 0.01) were greater in CS. FM significantly correlated (r2 = 0.23, P < 0.05) with leucine Ra and LIP, but not Lox, in CS. In multiple regression, LM was an independent determinant of all three indexes of leucine turnover, FM of leucine Ra, and LIP and CS of Lox. Following restoration of eucortisolemia, Lox was reduced (∆−7.5 ± 2.6 μmol/min, P = 0.02) and LIP increased (∆+15.2 ± 6.2 μmol/min, P = 0.04). In summary, whole body protein metabolism in CS is influenced by changes in body composition and glucocorticoid excess per se, which increases protein oxidation. Enhanced protein oxidation is a likely explanation for the reduced protein mass in CS. Successful treatment of CS reduces protein oxidation and increases protein synthesis to prevent ongoing protein loss.

whole body leucine turnover; body composition; resting energy expenditure

MAINTENANCE OF OPTIMAL BODY PROTEIN STATUS is an essential regulatory process for health. Protein loss causes substantial morbidity and increases mortality in chronic renal failure (31), acquired immunodeficiency syndrome (21), and chronic obstructive pulmonary disease (26). Protein mass is reduced in Cushing’s syndrome (3, 9, 49), resulting in skin thinning, muscle wasting, and weakness (36). Protein wasting may contribute directly or indirectly to the markedly increased mortality in untreated Cushing’s syndrome (34).

Body protein is constantly turned over, a process regulated by genetic, nutritional, behavioral, environmental, and hormonal factors. Steady-state tracer methodology, such as the

leucine turnover technique, has allowed accurate and noninvasive estimation of whole body rates of the three main components of protein metabolism: breakdown, oxidation, and synthesis. Protein mass is lost when the rate of protein breakdown is increased relative to synthesis or conversely if synthesis is reduced relative to breakdown. Both scenarios result in an increase in irreversible loss of amino acids by oxidation.

The acute impact of pharmacological doses of glucocorticoids on whole body protein metabolism has been well characterized; they increase protein breakdown relative to synthesis, thereby increasing protein oxidation (1, 10, 17). The impact of chronic glucocorticoid exposure on protein metabolism is controversial. This has been explored in Cushing’s syndrome, where protein breakdown and synthesis have been reported to be proportionately reduced (2) or not different from those in normal subjects (44). In both studies the rate of protein oxidation was similar to normal subjects (2, 44), an observation that is not consistent with the progressive protein loss that occurs in this condition. Cushing’s syndrome is associated with severe perturbations of body composition (3, 9, 49). Both lean body mass (LBM) (16, 51) and fat mass (FM) (46) influence rates of whole body protein metabolism. The above studies did not take into account the confounding effects of abnormal body composition (2, 44), and thus the status of protein metabolism in Cushing’s syndrome remains to be clarified.

The aim of this study was to assess the impact of chronic glucocorticoid excess and restoration of eucortisolemia on whole body protein metabolism after accounting for body composition differences in Cushing’s syndrome. With this in mind, we have undertaken two studies. First, a cross-sectional study compared whole body protein metabolism in subjects with Cushing’s syndrome with normal subjects matched for sex, age, and weight, and second, a longitudinal study assessed the impact of restoring eucortisolemia in subjects with Cushing’s syndrome.

MATERIALS AND METHODS

Subjects

Eighteen subjects (12 women) with active Cushing’s syndrome were recruited through St. Vincent’s Hospital, Department of Endocrinology, and 18 normal subjects (11 women) were recruited from the general population. The clinical characteristics of the group of subjects with Cushing’s syndrome participating in the cross-sectional study have been reported previously (3). The cause of Cushing’s syndrome was an ACTH-producing pituitary tumor in 15 subjects, bilateral micronodular adrenal hyperplasia in one subject, an adrenal
adrenalectomy in one subject, and ectopic ACTH secretion from a thymic carcinoid tumor in one subject. All subjects with Cushing’s syndrome had active disease as defined by an elevated 24-h urinary free cortisol (mean = 1,408 ± 333 nmol/day, normal <300 nmol/day). The mean duration of symptoms consistent with Cushing’s syndrome was 42 ± 9 mo. In 12 subjects Cushing’s syndrome was newly diagnosed, and these subjects were assessed prior to replacement of other pituitary hormone deficits (which were present in only 2 subjects). Central hypothroidism was present in one subject, and testosterone was below the lower limit of normal in one male subject. In six subjects (4 women), Cushing’s disease was persistent following transsphenoidal surgery, with one subject also previously receiving radiotherapy. These subjects were receiving replacement for other pituitary hormone deficits as appropriate, including thyroxine replacement (n = 3), with one male subject receiving testosterone replacement.

Ten subjects with Cushing’s syndrome were restudied on a second occasion, 13.6 ± 2.4 mo after their initial study, following successful treatment of Cushing’s syndrome. Treatment consisted of a transsphenoidal hypophysectomy (n = 6), bilateral adrenalectomy (n = 1), stereotactic pituitary radiotherapy (n = 2), and a transsphenoidal hypophysectomy followed by bilateral adrenalectomy (n = 1). Five subjects were on no glucocorticoid replacement with a normal 24-h urinary free cortisol, and five subjects were receiving physiological glucocorticoid replacement. Postoperatively, two subjects developed central hypothroidism. Both received physiological replacement therapy (thyroxine 100 µg/day) for ≥6 mo before the second study. The Research Ethics Committee of St. Vincent’s Hospital (Sydney, Australia) approved both studies, and all subjects provided written informed consent.

Experimental Protocol

Subjects attended the Clinical Research Facility, Garvan Institute of Medical Research, at 0830 after an overnight fast, where they underwent assessment of whole body protein metabolism and body composition.

Body composition. Body composition was assessed by dual-energy X-ray absorptiometry (DEXA) using a three-compartment model. FM, LBM, and bone mineral content (BMC) were measured using a total body scanner (Lunar model DPX, software version 3.1; Lunar, Madison, WI) that also quantified regional body composition of upper and lower limb along with truncal fat. Truncal fat comprises fat in the chest, abdominal, and pelvic regions, as previously described (4). At our institution the coefficients of variation (CVs) for FM and LBM are 2.9 and 1.4%, respectively (30).

Whole body protein turnover. Whole body protein turnover was assessed using a primed constant infusion of L-[13C]leucine, as previously described (11, 16, 53). NaHCO3 and 99% L-[13C]leucine were obtained from Cambridge Isotope Laboratories (Woburn, MA). Solutions were prepared under sterile conditions using 0.9% saline.

Following an overnight fast, a 0.1 mg/kg priming dose of NaHCO3 was immediately followed by a 3-h primed constant infusion of L-[13C]leucine (prime, 0.5 mg/kg; infusion, 0.5 mg·kg−1·h−1), based on previous studies (16, 53) demonstrating that steady state was achieved during this time period. Blood and breath samples were collected before (−10, 0 min) and at the end of the infusion (140, 160, and 180 min). Blood was placed on ice, and plasma was separated and stored at −80°C until analysis. Total CO2 production rates were measured with an open-circuit ventilated hood system (Deltatrac metabolic monitor; Datex Instrumentation, Helsinki, Finland) that was calibrated against standard gases before each study. Measurements of CO2 production were collected during two 20-min periods and averaged.

Calculation of whole body protein turnover. Rates of whole body protein turnover were calculated using the reciprocal pool method, as previously described (37), allowing calculation of rates of leucine appearance (leucine Ra; an index of protein breakdown), leucine oxidation (Lox; an index of oxidative loss of protein), and leucine incorporation into protein (LIP; an index of protein synthesis). The method is based on the principle of steady-state kinetics in which the rate of appearance of substrate equals its rate of disposal. For leucine there are two pathways of disposal: oxidation and reincorporation into protein. In the reciprocal pool method, α-ketoisocaprylic acid (KIC), formed when leucine undergoes transamination, is used as a surrogate marker of true intracellular leucine enrichment as intracellular and serum levels rapidly equilibrate (37). Because leucine represents 8% of total body protein, or 590 µmol leucine represents 1 g of protein, rates of protein turnover may be estimated using these constants (27). The CVs for leucine Ra, Lox, and LIP at our institution, based on seven subjects studied on two occasions, are 3.5, 6.1, and 3.5%, respectively.

Indirect calorimetry. O2 consumption and CO2 production were measured with the Deltatrac metabolic monitor, as described above. Resting energy expenditure (REE) and substrate oxidation rates were calculated using the equations of Ferrarini (8). At our institution, the mean day-to-day intrasubject CV for REE is ~4% (14, 29) and fat oxidation ~15% (unpublished data).

Analytical methods. KIC was extracted from plasma as described by Nissen et al. (28). KIC enrichment was measured as the butyl-dimethylsilyl derivative by gas chromatography (model 5890; Hewlett-Packard, Palo Alto, CA)-mass spectrometry (MSD 5972A; Hewlett-Packard), with selective monitoring of ions 301 and 302 (38). CO2 enrichment in breath was measured at St. Thomas’ Hospital, London, UK, on a SIRA Series II isotope ratio mass spectrometer (VG Isotec, Cheshire, UK).

Statistical analysis. Statistical analysis was undertaken using statistical software packages Statview 4.5 PPC (Abacus Concepts, Berkeley, CA) and SPSS 11.0 (SPSS, Chicago, IL). Results are expressed as means ± SE unless otherwise stated. Categorical variables were assessed using a chi-square test. Continuous variables were assessed using unpaired or paired t-tests as appropriate. When data were not normally distributed (changes in body composition with restoration of eucortisolemia), they were log transformed prior to statistical analysis; however, means are presented in the text nontransformed. Simple and multiple regression analyses were performed to examine the relationship between variables. Correction of whole body leucine turnover for the impact of differences in body composition was undertaken by analysis of covariance, rather than simple division by LBM, since this avoids any statistical bias arising from differences in body composition between the groups (35, 40, 42).

RESULTS

Cross-Sectional Study

Subject characteristics. There were no significant differences in sex distribution, age, weight, and body mass index between the groups of normal subjects and subjects with Cushing’s syndrome (Table 1).

Body composition. A detailed description of whole and regional body composition in the two groups has previously been reported (3). Percentage FM was significantly greater (P = 0.002) and LBM (P = 0.002) and BMC (P = 0.002) lower in subjects with Cushing’s syndrome (Table 1). Truncal fat (P = 0.0002) was significantly greater and lean arm and leg mass significantly lower (P < 0.0005 for both) in subjects with Cushing’s syndrome (Table 1).

Whole body leucine turnover. LBM was positively correlated with all three indexes of whole body leucine turnover in normal subjects and subjects with Cushing’s syndrome (Table 2). The correlation between leucine turnover and LBM was stronger in normal subjects than in subjects with Cushing’s syndrome (Table 2). After correction for LBM, leucine Ra and Lox were...
Table 1. Subject characteristics and whole and regional body composition of 18 normal subjects and 18 subjects with Cushing’s syndrome

<table>
<thead>
<tr>
<th>Normal Subjects</th>
<th>Cushing’s Syndrome</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F/M)</td>
<td>11/7</td>
<td>12/6</td>
</tr>
<tr>
<td>Age, yr</td>
<td>46.8±2.8</td>
<td>41.6±5.0</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>72.4±4.2</td>
<td>74.5±5.6</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.5±1.1</td>
<td>27.1±1.1</td>
</tr>
<tr>
<td>Fat mass, %*</td>
<td>33.8±2.4</td>
<td>43.9±1.6</td>
</tr>
<tr>
<td>Lean body mass, %*</td>
<td>62.1±2.3</td>
<td>52.7±1.6</td>
</tr>
<tr>
<td>BMC, %*</td>
<td>4.06±0.13</td>
<td>3.46±0.12</td>
</tr>
<tr>
<td>Truncal fat, %*</td>
<td>15.8±1.2</td>
<td>23.2±1.3</td>
</tr>
<tr>
<td>Lean arm mass, %*</td>
<td>7.6±0.3</td>
<td>5.9±0.2</td>
</tr>
<tr>
<td>Lean leg mass, %*</td>
<td>22.1±0.9</td>
<td>17.5±0.6</td>
</tr>
</tbody>
</table>

Values represent means ± SE. F/M, females/males; BMI, body mass index; BMC, bone mineral content; *Expressed as % total body weight.

significantly greater in subjects with Cushing’s syndrome than in normal subjects; LIP was also higher, but the difference did not reach statistical significance (P = 0.06; Table 3 and Fig. 1).

If indexes of whole body leucine turnover were unadjusted (Table 3 and Fig. 1) or expressed per kilogram of body weight (data not shown), no significant differences in any of the indexes of leucine metabolism between the groups were apparent.

In subjects with Cushing’s syndrome, FM was significantly positively correlated with leucine Ra and LIP, but not Lox (Table 2). The correlations between FM and leucine turnover in normal subjects were not statistically significant (Table 2). When FM was included as a covariate with LBM, Lox was significantly elevated in subjects with Cushing’s syndrome, whereas leucine Ra and LIP were not significantly different (Table 3 and Fig. 1). Age and 24-h urinary free cortisol were not significantly correlated with indexes of whole body leucine turnover (Table 2).

A multiple regression analysis was performed to determine the independent effects of LBM, FM, and glucocorticoid excess (Cushing’s syndrome defined as either present or absent) on whole body leucine turnover (Table 4). LBM was an independent determinant of all three indexes of whole body leucine turnover. FM was a significant independent determinant of leucine Ra and LIP, but not Lox. Cushing’s syndrome was an independent determinant of Lox, but not leucine Ra or LIP.

Longitudinal Study

Subject characteristics. Ten subjects were restudied after successful treatment of Cushing’s syndrome. Subjects had been eucortisolemic for an estimated 7.6 ± 1.3 mo. At the time of retesting, five subjects were on no glucocorticoid replacement with a mean 24-h urinary free cortisol of 139 ± 41 nmol/day. Five subjects were receiving physiological glucocorticoid replacement (prednisone 2.5–5 mg/day).

Body composition. Following successful treatment of Cushing’s syndrome, mean weight fell by 4.2 ± 3.2 kg; however, the change was not statistically significant (P = 0.23). There were no significant changes in absolute FM or LBM (Table 5), although the fall in FM approached statistical significance (P = 0.098). Percent FM fell significantly, by 4.6 ± 2.0% (P = 0.046), and percent LBM increased by 4.4 ± 1.9% (P = 0.045) with successful treatment of Cushing’s syndrome.

Whole body leucine turnover. Changes in leucine metabolism were analyzed after correction for changes in LBM. Following successful treatment of Cushing’s syndrome, Lox fell (P = 0.02) and LIP increased (P = 0.04) significantly, whereas leucine Ra did not change (Fig. 2). There were no significant differences in LBM-adjusted leucine Ra (Δ + 9.3 ± 6.8 μmol/min, P = 0.18), Lox (Δ −3.2 ± 2.1 μmol/min, P = 0.13), and LIP (Δ+12.5 ± 6.6 μmol/min, P = 0.07) between treated subjects with Cushing’s syndrome and normal subjects.

Indirect calorimetry. There were no significant changes in REE (1,431 ± 79 vs. 1,385 ± 62 kcal/day, P = 0.49), fat oxidation (71.5 ± 10.5 vs. 79.7 ± 10.3 mg/min, P = 0.57), or carbohydrate oxidation (55.2 ± 22.0 vs. 31.2 ± 20.2 mg/min, P = 0.41) following successful treatment of Cushing’s syndrome. Results were not significantly different after correction for the change in LBM (data not shown).

DISCUSSION

This is the first study assessing postabsorptive whole body protein metabolism in Cushing’s syndrome that accounts for the confounding effects of differences in body composition and the first to assess LBM-adjusted changes in protein metabolism after successful treatment. Percentage FM was significantly greater and LBM and BMC lower in Cushing’s syndrome. LBM significantly and positively influenced all indexes of leucine turnover in both groups. In the cross-sectional study, comparison of raw unadjusted data revealed no difference in any of the indexes of leucine turnover between subjects with Cushing’s syndrome and normal subjects. After correction for the reduced LBM, Lox was significantly higher in Cushing’s, brought about by a greater increase in leucine Ra than LIP. FM significantly and positively influenced leucine Ra and LIP in subjects with Cushing’s syndrome. After accounting for the difference of FM and LBM, patients with Cushing’s syndrome displayed a significant increase in Lox only. In the longitudinal study, restoration of eucortisolism resulted in a significant reduction in percentage FM and a reciprocal increase in percentage LBM. This was associated with a significant reduction in Lox and an increase in LIP to a level indistinguishable from normal subjects.

This study shows that elucidation of the effect of glucocorticoid excess on postabsorptive whole body protein metab-

Table 2. Simple regression analyses of correlation between leucine Ra, Lox, and LIP and LBM, FM, age, and 24-h UFC in 18 normal subjects and 18 subjects with Cushing’s syndrome

<table>
<thead>
<tr>
<th>Normal Subjects</th>
<th>Cushing’s Syndrome</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leucine Ra</td>
<td>Lox</td>
<td>LIP</td>
</tr>
<tr>
<td>LBM, kg</td>
<td>0.84†</td>
<td>0.69†</td>
</tr>
<tr>
<td>FM, kg</td>
<td>0.15</td>
<td>0.02</td>
</tr>
<tr>
<td>Age, yr</td>
<td>0.14</td>
<td>0.14</td>
</tr>
<tr>
<td>UFC, nmol/day</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Leucine Ra, rate of leucine appearance; Lox, leucine oxidation; LIP, leucine incorporation into protein; LBM, lean body mass; FM, fat mass; UFC, urinary free cortisol; NA, not assessed. Figures denote r² values. *P < 0.05; †P < 0.005.
Glucocorticoids increase fasting and postprandial Lox to a rate of protein loss of 4.5 kg/yr. Matthews et al. (27), a difference in Lox of 5 mg/min following successful treatment, although the changes were not statistically significant. Carbohydrate oxidation is unlikely to be reduced, since this tended to be higher in Cushing’s syndrome and fell with successful treatment. The day-to-day reproducibility in the assessment of fat oxidation by indirect calorimetry is relatively poor (47, 52) and is likely to have contributed to the failure to find a statistically significant change.

Contrary to a proposed direct effect of glucocorticoid excess on protein oxidation, postabsorptive leucine Ra and LIP were independently related to FM in subjects with Cushing’s syndrome and not glucocorticoid excess. A similar relationship between adiposity and leucine Ra and LIP has previously been reported in healthy women (46), with most (5, 19, 20, 50), but not all (41), studies reporting that LBM-adjusted leucine Ra and LIP are increased in obesity. However, the mechanisms by which FM influences leucine turnover are unclear. Whereas adipose tissue accounts for 6–12% of whole-body proteolysis (7, 32), the contribution of adipose tissue to leucine turnover is similar in lean and markedly obese individuals (32). This suggests that the increased leucine Ra in obesity is not because of increased protein breakdown within adipose tissue but that adipose tissue may influence protein breakdown in lean tissue via an indirect mechanism. Speculation on the relationship between FM and leucine Ra has centered on the possibility that the increased leucine Ra in obesity may arise from reduced sensitivity to insulin. Insulin-induced inhibition of proteolysis is attenuated in obese (25) and insulin-resistant subjects (15, 45). However, no correlation was found between leucine Ra and insulin sensitivity measured by euglycemic hyperinsuline-
Following treatment of Cushing’s syndrome there was a significant fall in percentage FM and an increase in percentage, but not absolute, LBM. Previous studies (23, 33, 48) have reported that, although successful control of glucocorticoid excess in Cushing’s syndrome reduces FM, LBM remains subnormal and does not significantly increase. We found that postabsorptive $L_{\text{ox}}$ fell and LIP increased after successful treatment, whereas leucine $R_a$ was not significantly affected. Therefore, a greater proportion of amino acids generated from protein breakdown are reincorporated back into protein rather than oxidized. However, $L_{\text{ox}}$ was reduced to the level of normal subjects, not significantly below it, which is necessary for protein anabolism. It is possible that we missed a transient normal subjects, which is necessary for protein anabolism. It is possible that we missed a transient.

A limitation of the whole body leucine turnover technique is that the results represent the net effect in all tissues and do not provide information on regional contribution to protein turnover. There is major interest in the impact of glucocorticoid excess on skeletal muscle protein metabolism, since limb lean tissue is preferentially lost in Cushing’s syndrome (3, 9, 49). Although skeletal muscle represents the largest mass of body protein, it accounts for only 30–50% of whole body protein breakdown, oxidation, and synthesis (43). Therefore, changes in whole body protein metabolism may not reflect that in skeletal muscle. In contrast to the acute glucocorticoid-induced increase in whole body protein breakdown and oxidation, forearm and lower limb studies (22, 24, 39) have not observed any significant change in skeletal muscle protein metabolism following acute glucocorticoid administration in the postabsorptive state. However, one study (12) reported a reduction in skeletal muscle fractional synthesis rate in subjects on long-term glucocorticoids. The discrepancy between whole body and regional studies may reflect a greater effect of glucocorticoids on nonskeletal protein sources, such as the splanchnic bed, or the sensitivity or end points of the method under conditions of the study. For example, regional studies based on arteriovenous differences in amino acid enrichment do not directly quantify amino acid oxidation, which was increased in the whole body study.

Despite our efforts to correct data for body compositional change, it is not possible to account for all variables that could influence protein metabolism in a cross-sectional study. We (3) have previously reported that the mean extracellular water volume was not significantly different in a subset of the subjects from each group, and therefore, hydration of the LBM is unlikely to affect results. Furthermore, it is unlikely that deficiencies of other hormones significantly influenced results. Although subjects were not formally evaluated for growth hormone (GH) deficiency, protein oxidation in GH-deficient adults is not significantly different to normal subjects (16). The one subject with untreated androgen deficiency is unlikely to have markedly confounded results, and omission of this subject’s data did not influence the findings. The paired longitudinal data, where restoration of eucortisolemia resulted in a reduction in $L_{\text{ox}}$ with no change in leucine $R_a$, corroborate the cross-sectional data showing that the independent effect of glucocorticoid excess is to increase $L_{\text{ox}}$. Increased protein oxidation in Cushing’s syndrome is likely to be directly related to glucocorticoid excess.

In conclusion, we have shown that postabsorptive whole body protein metabolism in Cushing’s syndrome is influenced both by changes in body composition and by glucocorticoid excess per se. By accounting for the changes in FM and LBM in Cushing’s syndrome, we have shown that glucocorticoid excess causes a sustained but reversible stimulation of protein oxidation. This observation reconciles previous reports (2, 44) finding no perturbation in protein oxidation, which is at odds with clinical observations. Restoration of eucortisolemia results in a redistribution of amino acids from oxidative to synthetic pathways to prevent further protein loss.

**ACKNOWLEDGMENTS**

We thank the clinical research nurses and in particular Angela Peris and Margot Hewett for assistance with whole body leucine turnover studies, Dr. David Hoffman, Dr. Troels Wolthers, and Associate Prof. Gudmundur Johannsson for assistance with subject recruitment and whole body leucine turnover studies, Dr. Tuan Nguyen for statistical advice. Ann Poljak from the Bioanalytical Mass Spectrometry Facility, University of New South Wales, for assistance with gas chromatography-mass spectrometry, and Prof. Margot

---

**Table 5. Whole body composition in 10 subjects with Cushing’s syndrome before and after restoration of eucortisolemia**

<table>
<thead>
<tr>
<th></th>
<th>Before Treatment</th>
<th>After Treatment</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fat mass, kg</td>
<td>32.1±3.3</td>
<td>27.2±2.1</td>
<td>0.098</td>
</tr>
<tr>
<td>Fat mass, %*</td>
<td>43.7±2.4</td>
<td>39.0±2.4</td>
<td>0.046</td>
</tr>
<tr>
<td>LBM, kg</td>
<td>38.2±2.7</td>
<td>39.9±2.6</td>
<td>0.14</td>
</tr>
<tr>
<td>LBM, %*</td>
<td>53.1±2.3</td>
<td>57.5±2.3</td>
<td>0.045</td>
</tr>
<tr>
<td>BMC, kg</td>
<td>2.3±0.1</td>
<td>2.4±0.1</td>
<td>0.34</td>
</tr>
<tr>
<td>BMC, %*</td>
<td>3.3±0.2</td>
<td>3.4±0.1</td>
<td>0.45</td>
</tr>
</tbody>
</table>

Values represent means ± SE. %Expressed as a %body weight.

---

**Fig. 2.** Change in leucine $R_a$, $L_{\text{ox}}$, and LIP in 10 subjects with Cushing’s syndrome after successful therapy. Leucine turnover is adjusted for the change in lean body mass using analysis of covariance. $P$ values relate to the change in leucine turnover following therapy, and differences are expressed as means ± SE. NS, not significant.
Umpleby and Dr. Nicola Jackson from the Department of Diabetes and Endocrinology, Guy’s, King’s and St. Thomas’ School of Medicine, St. Thomas’ Hospital, London, UK, for assistance with measurement of CO2 enrichment.

GRANTS

M. G. Burt is supported by a scholarship from the National Health and Medical Research Council of Australia.

REFERENCES


AJP-Endocrinol Metab • VOL 292 • MAY 2007 • www.ajpendo.org


